Medicare Enrolled

Dr. Thomas Raper, M.D.

Pulmonary Disease · Dallas, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
8220 WALNUT HILL LN STE 408, Dallas, TX 75231
2143619777
In practice since 2006 (19 years)
NPI: 1417995044 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Raper from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Raper? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Raper

Dr. Thomas Raper is a pulmonary disease in Dallas, TX, with 19 years in practice. Based on federal Medicare data, Dr. Raper performed 942 Medicare services across 673 unique beneficiaries.

Between the years covered by Open Payments, Dr. Raper received a total of $6,564 from 34 pharmaceutical and/or device companies across 204 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Raper is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 49% volume in TX$ $6,564 industry payments

Medicare Practice Summary

Medicare Utilization ↗
942
Medicare services
Top 49% in TX for pulmonary disease
673
Unique beneficiaries
$93
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~50 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Hospital follow-up visit, high complexity206$95$718
Critical care, first 30-74 min186$167$1,534
Office visit, established patient (20-29 min)92$67$473
Office visit, established patient (30-39 min)92$94$693
Test to measure expiratory airflow and volume91$20$191
Initial hospital admission, high complexity45$137$1,389
Hospital follow-up visit, moderate complexity42$64$500
Test to measure expiratory airflow and volume changes before and after medication administration40$30$264
Test to examine how well the lungs exchange gases36$39$380
Sleep study including heart rate, breathing, and sleep time16$38$345
New patient office visit (30-44 min)16$91$592
Sleep study in sleep lab (6 years or older)15$95$844
Initial hospital admission, moderate complexity15$105$948
Test to determine lung volumes using sensors14$43$391
New patient office visit (45-59 min)13$114$957
Test for exercise-induced lung stress12$16$158
Office visit, established patient, complex (40-54 min)11$132$1,030
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$6,564
Total received (2018-2024)
Avg $938/year across 7 years
Top 28% in TX for pulmonary disease
34
Companies
204
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,153 (63.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,412 (21.5%)
Scientific / Research
Research funding and grants
$1,000 (15.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,019
2023
$398
2022
$229
2021
$130
2020
$1,123
2019
$1,058
2018
$2,608

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
La Jolla Pharmaceutical Company
$1,358
GlaxoSmithKline, LLC.
$1,030
Genentech, Inc.
$1,000
AstraZeneca Pharmaceuticals LP
$447
Inari Medical, Inc.
$353
Boehringer Ingelheim Pharmaceuticals, Inc.
$337
GENZYME CORPORATION
$291
Sunovion Pharmaceuticals Inc.
$188
Mylan Specialty L.P.
$186
Inspire Medical Systems, Inc.
$145
ABIOMED
$145
Pulmonx Corporation
$137
Philips Electronics North America Corporation
$90
Electromed, Inc.
$83
Genentech USA, Inc.
$77
Merck Sharp & Dohme LLC
$76
Grifols USA, LLC
$61
JAZZ PHARMACEUTICALS INC.
$59
Resmed Corp
$54
Actelion Pharmaceuticals US, Inc.
$49
Insmed, Inc.
$46
Itamar Medical Inc
$41
Mallinckrodt Enterprises LLC
$39
Shire North American Group Inc
$35
Mallinckrodt LLC
$33
Chiesi USA, Inc.
$32
Teva Pharmaceuticals USA, Inc.
$31
United Therapeutics Corporation
$30
ABBVIE INC.
$24
Merck Sharp & Dohme Corporation
$24
MAYNE PHARMA INC.
$19
Philips North America LLC
$17
Inogen, Inc.
$14
Jazz Pharmaceuticals Inc.
$14
Top 3 companies account for 51.6% of total payments
Associated products mentioned in payments ›
(2791) CoughAssist · (8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSENSE · ANORO · Arikayce · BEVESPI AEROSPHERE · BREO · BREZTRI · BROVANA · CARDENE · CHARTIS CATHETER · DIFICID · DORYX · DUPIXENT · Dymista · Esbriet · FASENRA · FLOWTRIEVER CATHETER · GIAPREZA · GLASSIA · INSPIRE · Impella · InogenOne · LONHALA MAGNAIR · NUCALA · OFEV · OPSUMIT MACITENTAN · ORENITRAM · Perforomist · Prolastin-C Liquid · Respiratoriy Care Undiv · S · SHINGRIX · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · Trilogy 100 · UPTRAVI · WatchPAT · WatchPATONE · XYWAV · Xolair · Xyrem · Yupelri · ZERBAXA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (63%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $697 per 100 Medicare services performed
Looking for a pulmonary disease in Dallas?
Compare pulmonary diseases in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary Diseases within 10 mi
123
Per 100K population
4.7
County median income
$74,149
Nearest hospital
TEXAS HEALTH PRESBYTERIAN HOSPITAL DALLAS
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Raper is a clinical cardiology specialist, with moderate Medicare volume, and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Raper experienced with hospital follow-up visit, high complexity?
Based on Medicare claims data, Dr. Raper performed 206 hospital follow-up visit, high complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Raper receive payments from pharmaceutical companies?
Yes. Dr. Raper received a total of $6,564 from 34 companies across 204 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Raper's costs compare to other pulmonary diseases in Dallas?
Dr. Raper's average Medicare payment per service is $93. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Raper) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →